Stockreport

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside [Seeking Alpha]

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
PDF The new ALPHA3 clinical trial for Allogene's Cema-Cel cancer treatment is set to begin in mid-2024, and if successful, investors could see significant returns on their [Read more]